{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:52:51Z","timestamp":1790016771545,"version":"4.0.1"},"reference-count":19,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background and Aims: The IL-12\/23 inhibitor ustekinumab (UST) opened up new treatment options for patients with Crohn\u2019s disease (CD). Due to the recent approval, real-world German data on long-term efficacy and safety are lacking. This study aimed to assess the clinical course of CD patients under UST therapy and to identify potential predictive markers. Methods: Patients with CD receiving UST treatment in three hospitals and two outpatient centers were included and retrospectively analyzed. Rates for short- and long-term remission and response were analyzed with the help of clinical (Harvey\u2013Bradshaw Index (HBI)) and biochemical (C-reactive protein (CRP), Fecal calprotectin (fCal)) parameters for disease activity. Results: Data from 180 patients were evaluated. One-hundred-and-six patients had a follow-up of at least eight weeks and were included. 96.2% of the patients were pre-exposed to anti- TNF\u03b1 agents and 34.4% to both anti-TNF\u03b1 and anti-integrin antibodies. The median follow-up was 49.1 weeks (95% CI 42.03-56.25). At week 8, 51 patients (54.8%) showed response to UST, and 24 (24.7%) were in remission. At week 48, 48 (51.6%) responded to UST, and 25 patients (26.9%) were in remission. Steroid-free response and remission at week eight was achieved by 30.1% and 19.3% of patients, respectively. At week 48, 37.6% showed steroid-free response to UST, and 20.4% of the initial patient population was in steroid-free remission. Conclusion: Our study confirms short- and long-term UST effectiveness and tolerability in a cohort of multi-treatment-exposed patients.<\/jats:p>","DOI":"10.3390\/jcm8122140","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T03:16:36Z","timestamp":1575515796000},"page":"2140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn\u2019s Disease: Real-World Data from a German IBD Cohort"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-6088","authenticated-orcid":false,"given":"Alica","family":"Kubesch","sequence":"first","affiliation":[{"name":"Department of Medicine 1, Goethe University Hospital, 60590 Frankfurt a.M., Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurenz","family":"Rueter","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, Goethe University Hospital, 60590 Frankfurt a.M., Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Farrag","sequence":"additional","affiliation":[{"name":"Interdisciplinary Crohn-Colitis Centre Rhein-Main, 60590 Frankfurt a.M., Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krause","sequence":"additional","affiliation":[{"name":"Gastroenterological Practice, 34117 Kassel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Stienecker","sequence":"additional","affiliation":[{"name":"Gastroenterological Practice, 36039 Fulda, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5217-2301","authenticated-orcid":false,"given":"Johannes","family":"Hausmann","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, Goethe University Hospital, 60590 Frankfurt a.M., Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Filmann","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Mathematical Modeling, University Hospital, Goethe University, 60590 Frankfurt a. M., Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Agaplesion Markus Krankenhaus, 60590 Frankfurt a. M., Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Stein","sequence":"additional","affiliation":[{"name":"Interdisciplinary Crohn-Colitis Centre Rhein-Main, 60590 Frankfurt a.M., Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Blumenstein","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, Goethe University Hospital, 60590 Frankfurt a.M., Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomized trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: Evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/138945010790309894","article-title":"How to Manage Loss of Response to Anti-TNF in Crohns Disease?","volume":"11","author":"Reinisch","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","article-title":"Novel Targeted Therapies for Inflammatory Bowel Disease","volume":"38","author":"Coskun","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/apt.15371","article-title":"Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn\u2019s disease: Results from the ENEIDA registry","volume":"50","author":"Iborra","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.crohns.2014.06.005","article-title":"Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn\u2019s disease-The McGill experience","volume":"8","author":"Kopylov","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MIB.0000000000000624","article-title":"Patients with Refractory Crohn\u2019s Disease Successfully Treated with Ustekinumab","volume":"22","author":"Harris","year":"2016","journal-title":"Inflamm. Bowel Dis"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Liefferinckx, C., Verstockt, B., Gils, A., Noman, M., Van Kemseke, C., Macken, E., De Vos, M., Van Moerkercke, W., Rahier, J.F., and Bossuyt, P. (2019). Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn\u2019s Disease Who Failed Biologic Therapies: A National Cohort Study. J. Crohn\u2019s Colitis.","DOI":"10.1093\/ecco-jcc\/jjz080"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/apt.14487","article-title":"Long-term efficacy and safety of ustekinumab in 122 refractory Crohn\u2019s disease patients: A multicentre experience","volume":"47","author":"Wils","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Biemans, V.B.C., van der Meulen-de Jong, A.E., van der Woude, C.J., L\u00f6wenberg, M., Dijkstra, G., Oldenburg, B., de Boer, N.K., van der Marel, S., Bodelier, A.G., and Jansen, J.M. (2019). Ustekinumab for Crohn\u2019s disease: Results of the ICC Registry, a nationwide prospective observational cohort study. J. Crohn\u2019s Colitis.","DOI":"10.1093\/ecco-jcc\/jjz119"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/gut.49.6.777","article-title":"Behavior of Crohn\u2019s disease according to the Vienna classification: Changing pattern over the course of the disease","volume":"49","author":"Louis","year":"2001","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"ref_15","first-page":"357","article-title":"Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity","volume":"8","author":"Vermeire","year":"2010","journal-title":"Hepatol"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1756283X15618130","article-title":"Ustekinumab for the treatment of Crohn\u2019s disease: Can it find its niche?","volume":"9","author":"Simon","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","first-page":"jjz110","article-title":"IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn\u2019s Disease","volume":"3","author":"Feagan","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_19","first-page":"706","article-title":"Safety Surveillance for Ustekinumab and Other Psoriasis Treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J. Drugs Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/12\/2140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:40:04Z","timestamp":1760190004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/12\/2140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["jcm8122140"],"URL":"https:\/\/doi.org\/10.3390\/jcm8122140","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,4]]}}}